83. Infectious Outcomes of CAR T-cell Therapy: Longitudinal Follow Up and Risk Stratification

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 is increasingly utilized in the treatment of a variety of hematologic malignancies. While efficacious, this therapy is associated with prolonged cytopenias and immunosuppression. Open questions remain regarding the distributio...

Descripción completa

Detalles Bibliográficos
Autores principales: Czapka, Michael, Riedell, Peter A, Pisano, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752853/
http://dx.doi.org/10.1093/ofid/ofac492.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752853/
http://dx.doi.org/10.1093/ofid/ofac492.008

Ejemplares similares